Press releases

Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on May 4

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022 Annual Report has been published

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 25 May 2023 at 3 p.m. Registration for attendees will commence at 2.30 p.m

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company presents new scientific data on melflufen at the European Myeloma Network meeting in Amsterdam on April 20. The data includes one abstract on health-related quality of life outcomes from the phase 3 OCEAN study, and one abstract from the phase 3 LIGHTHOUSE study

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has received a research grant of 3 MSEK from Sweden´s Innovation Agency (Vinnova), to explore the development of new treatment options for glioblastoma, an aggressive and incurable form of brain cancer. The grant enables exploratory research to better understand the potential of the PDC platform in solid tumors such as glioblastoma

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been informed that the company’s Chief Scientific Officer Jakob Lindberg was today released from custody. This, after being arrested on Wednesday March 8th, allegedly for unauthorized disclosure of inside information in October 2021

Oncopeptides AB (publ), has been informed by the Swedish Economic Crime Authority that the CSO Jakob Lindberg has been arrested for a suspected violation of the Market Abuse Act (Sw. lag om straff för marknadsmissbruk på värdepappersmarknaden)

Oncopeptides AB (publ), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2022

Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth quarter and the 2022 year-end report, at 08:00 (CET) on February 16, 2023

STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases, today announces that Holger Lembrer, who recently was appointed Chief Financial Officer, CFO, takes the office on January 18